Rosuvastatin reduces the recurrence rate following catheter ablation for atrial fibrillation in patients with heart failure

Zhao,Guojun; Wu,Leiming; Liu,Yuzhou; Gao,Lu; Chen,Yang; Yao,Rui; Zhang,Yanzhou

doi:10.3892/br.2017.844

Rosuvastatin reduces the recurrence rate following catheter ablation for atrial fibrillation in patients with heart failure

Authors:
- Guojun Zhao
- Leiming Wu
- Yuzhou Liu
- Lu Gao
- Yang Chen
- Rui Yao
- Yanzhou Zhang
View Affiliations

Affiliations: Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: January 17, 2017 https://doi.org/10.3892/br.2017.844
Pages: 346-352

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to assess whether rosuvastatin could reduce the recurrence rate of atrial fibrillation (AF) in patients with heart failure (HF) following catheter ablation (CA). A total of 107 patients with HF and AF who underwent CA of AF by endocardial mapping and radiofrequency between June 2012 and May 2014 were recruited. The patients were randomly divided into three subgroups: i) Administered with 10 mg rosuvastatin daily following ablation (group 1, n=36); ii) administered with 20 mg rosuvastatin daily following ablation (group 2, n=36); and iii) only treated with conventional treatment of HF following ablation (group 3, n=35). After the procedure, patients were followed in the outpatient clinic by interrogation of Holter monitoring. The AF recurrence rate of group 2 was low in comparison with group 1 (22.2% vs. 38.9%, P=0.013) and group 3 (22.2% vs. 48.6%, P=0.021). In comparison with baseline, the parameters of the left ventricular ejection fraction, left atrial diameter (LAD), and the levels of N‑terminal pronatriuretic peptide and hypersensitive C‑reactive protein (hs‑CRP) were all improved in three groups. Furthermore, multivariate analysis demonstrated that LAD [hazard ratio (HR): 1.12, 95% confidence interval (CI): 1.06‑1.67, P=0.049], hs‑CRP (HR: 1.37, 95% CI: 1.11‑1.92, P=0.002) and duration of AF (HR: 1.14, 95% CI: 1.09‑1.18, P=0.011) were independent predictors of AF recurrence in patients with HF following CA. Therefore, the present study has demonstrated that treatment with 20 mg rosuvastatin daily following CA was able to significantly decrease the recurrence rate of AF in patients with HF, and LAD, hs‑CRP, and duration of AF were independent predictors of AF recurrence in patients with HF following CA. In conclusion, the present study has also demonstrated that CA may improve cardiac function in patients with HF and AF.

View Figures

View References

1	Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ and Levy D: Framingham Heart Study: Lifetime risk for developing congestive heart failure-The Framingham Heart Study. Circulation. 106:3068–3072. 2002. View Article : Google Scholar : PubMed/NCBI
2	Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA and Benjamin EJ: Lifetime risk for development of atrial fibrillation - The Framingham Heart Study. Circulation. 110:1042–1046. 2004. View Article : Google Scholar : PubMed/NCBI
3	Anselmino M, Matta M and Gaita F: Catheter ablation of atrial fibrillation in patients with heart failure: Can we break the vicious circle? Eur J Heart Fail. 17:1003–1005. 2015. View Article : Google Scholar : PubMed/NCBI
4	Cooper HA, Bloomfield DA, Bush DE, Katcher MS, Rawlins M, Sacco JD and Chandler M: AFFIRM Investigators: Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] Study). Am J Cardiol. 93:1247–1253. 2004. View Article : Google Scholar : PubMed/NCBI
5	January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, et al: ACC/AHA Task Force Members: 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 130:2071–2104. 2014. View Article : Google Scholar : PubMed/NCBI
6	Anselmino M, Matta M, D'Ascenzo F, Bunch TJ, Schilling RJ, Hunter RJ, Pappone C, Neumann T, Noelker G, Fiala M, et al: Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: A systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 7:1011–1018. 2014. View Article : Google Scholar : PubMed/NCBI
7	Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B and Ravid S: Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol. 92:1379–1383. 2003. View Article : Google Scholar : PubMed/NCBI
8	Horwich TB, MacLellan WR and Fonarow GC: Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 43:642–648. 2004. View Article : Google Scholar : PubMed/NCBI
9	Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, Nicolosi GL, Porcu M, Cosmi F, Stefanelli S, et al: GISSI-HF Investigators: Effects of rosuvastatin on atrial fibrillation occurrence: Ancillary results of the GISSI-HF trial. Eur Heart J. 30:2327–2336. 2009. View Article : Google Scholar : PubMed/NCBI
10	Xia W, Yin Z, Li J, Song Y and Qu X: Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol. 32:1562–1566. 2009. View Article : Google Scholar : PubMed/NCBI
11	Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, et al: American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines: 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 62:e147–e239. 2013. View Article : Google Scholar : PubMed/NCBI
12	Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, et al: American College of Cardiology, American Heart Association Task Force on Practice Guidelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation. 112:e154–e235. 2005. View Article : Google Scholar : PubMed/NCBI
13	Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al: ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol. 69:11672016.PubMed/NCBI
14	Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, Ito S, Makino H, Hishida A and Matsuo S: Modification of the modification of diet in Renal Disease (MDRD) study equation for Japan. Am J Kidney Dis. 50:927–937. 2007. View Article : Google Scholar : PubMed/NCBI
15	Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, Goromonzi F, Sawhney V, Duncan E, Page SP, et al: A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 7:31–38. 2014. View Article : Google Scholar : PubMed/NCBI
16	Thihalolipavan S and Morin DP: Atrial fibrillation and heart failure: Update 2015. Prog Cardiovasc Dis. 58:126–135. 2015. View Article : Google Scholar : PubMed/NCBI
17	Machino-Ohtsuka T, Seo Y, Ishizu T, Sugano A, Atsumi A, Yamamoto M, Kawamura R, Machino T, Kuroki K, Yamasaki H, et al: Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol. 62:1857–1865. 2013. View Article : Google Scholar : PubMed/NCBI
18	Maron DJ, Fazio S and Linton MF: Current perspectives on statins. Circulation. 101:207–213. 2000. View Article : Google Scholar : PubMed/NCBI
19	Liao JK and Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 45:89–118. 2005. View Article : Google Scholar : PubMed/NCBI
20	Kim YM, Guzik TJ, Zhang YH, Zhang MH, Kattach H, Ratnatunga C, Pillai R, Channon KM and Casadei B: A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res. 97:629–636. 2005. View Article : Google Scholar : PubMed/NCBI
21	Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM, Alp NJ, Schotten U and Casadei B: Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: Implications for the antiarrhythmic effect of statins. Circulation. 124:1107–1117. 2011. View Article : Google Scholar : PubMed/NCBI
22	Recalde A, Carnicer R, Simon J, Reilly S, Verheule S, Shah AM, et al: Increased atrial fibrillation susceptibility in mice with myocardial specific NOX2 overexpression is prevented by short term statin treatment. Eur Heart J. 35:11182014.
23	Peña JM, MacFadyen J, Glynn RJ and Ridker PM: High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: An exploratory analysis of the JUPITER trial. Eur Heart J. 33:531–537. 2012. View Article : Google Scholar : PubMed/NCBI
24	Walfridsson H, Walfridsson U, Nielsen JC, Johannessen A, Raatikainen P, Janzon M, Levin LA, Aronsson M, Hindricks G, Kongstad O, et al: Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: Results on health-related quality of life and symptom burden. The MANTRA-PAF trial. Europace. 17:215–221. 2015. View Article : Google Scholar : PubMed/NCBI
25	Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, Sterns LD, Beresh H, Healey JS and Natale A: RAAFT-2 investigators: Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): A randomized trial. JAMA. 311:692–700. 2014. View Article : Google Scholar : PubMed/NCBI
26	Rillig A, Makimoto H, Wegner J, Lin T, Heeger C, Lemes C, Fink T, Metzner A, Wissner E, Mathew S, et al: Six-year clinical outcomes after catheter ablation of atrial fibrillation in patients with impaired left ventricular function. J Cardiovasc Electrophysiol. 26:1169–1179. 2015. View Article : Google Scholar
27	Takagi H and Umemoto T: Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: A meta-analysis of randomized trials. Int J Cardiol. 155:296–299. 2012. View Article : Google Scholar : PubMed/NCBI
28	Loricchio ML, Cianfrocca C, Pasceri V, Bianconi L, Auriti A, Calo L, Lamberti F, Castro A, Pandozi C, Palamara A, et al: Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol. 99:1421–1424. 2007. View Article : Google Scholar : PubMed/NCBI
29	Schiffrin EL: The immune system: Role in hypertension. Can J Cardiol. 29:543–548. 2013. View Article : Google Scholar : PubMed/NCBI
30	Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, Odim J, Laks H and Sen L: Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation. 109:363–368. 2004. View Article : Google Scholar : PubMed/NCBI
31	Jalife J and Kaur K: Atrial remodeling, fibrosis, and atrial fibrillation. Trends Cardiovasc Med. 25:475–484. 2015. View Article : Google Scholar : PubMed/NCBI